Ontario confirms first case of blood clot after AstraZeneca shot

James Marshall
April 24, 2021

Ontario has reported its first confirmed case of vaccine-induced immune thrombotic thrombocytopenia (VITT) in a patient after receiving the AstraZeneca/COVISHIELD vaccine.

It said it wasn't known whether the risk of a rare blood clot after a second dose might be different than that engendered by the first shot.

"In these cases, the individuals concerned sought medical attention, received specialist medical care and are reported to be responding well to treatment", the HPRA said. According to data from the United Kingdom, which has administered more AstraZeneca doses than any other country, there were 30 such cases among 18 million inoculations as of late March.

Williams adds that while the serious reaction remains extremely rare, his team has a robust process in place to monitor for any adverse events and have taken steps to make sure that these specific cases are identified and treated as quickly as possible.

Canada's National Advisory Committee on Immunization (NACI) did advise provinces to pause the use of the AstraZeneca-Oxford COVID-19 vaccine in people under the age of 55 because of the safety concerns.

However, with COVID-19 cases rising province-wide and mounting criticism with the pace of vaccination, Ontario and other provinces chose to offer it to residents 40-years and up this week.

Some European countries have restricted use of the AstraZeneca vaccine to older age groups, citing the risk of such clots in younger people.

Dr. Williams stresses the Health Canada approved vaccines are the best way to protect your health and those around you and you should get your shot as soon as you're eligible.

Moderna and the Defense Health Agency conducted a review and determined the doses nevertheless pose no risk to those at Fort Meade who received them.

More details to come.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER